TMEM184B: A Transmembrane Protein Target for Drug Development and Cancer Treatment

Target Name: TMEM184B

NCBI ID: G25829

TMEM184B

TMEM184B: A Transmembrane Protein Target for Drug Development and Cancer Treatment

TMEM184B (Transmembrane protein 184B, transcript variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and kidneys. Its primary function is to regulate the movement of ions and molecules across the membrane of cells, which is a critical process for maintaining the proper functioning of cells and the organism as a whole.

Recent studies have identified TMEM184B as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and subcellular localization make it an attractive target for small molecules and antibodies that can modulate its function and disrupt its role in disease progression.

Disease-Benefit Relationships

TMEM184B has been linked to the development and progression of various diseases, including cancer. Its functions in cell signaling and ion regulation have been implicated in the development of these diseases, and targeting TMEM184B has been shown to be a promising strategy for cancer treatment.

One of the key benefits of targeting TMEM184B is its potential to disrupt the function of cancer cells. Cancer cells have unique requirements for ion regulation, and TMEM184B plays a critical role in this process. By inhibiting TMEM184B's function, cancer cells may be unable to maintain their normal growth and survival, leading to the development of a more aggressive and treatable form of cancer.

Another benefit of targeting TMEM184B is its potential to target a wide range of cancer types. TMEM184B is expressed in many different types of cancer cells, including brain, breast, lung, and ovarian cancers, making it an attractive target for cancer treatments that can be effective across different types of cancer.

Targeting TMEM184B

There are several strategies that can be used to target TMEM184B, including small molecule inhibitors, antibodies, and genetic modifiers.

Small molecule inhibitors are a popular approach for targeting TMEM184B. These drugs work by binding to TMEM184B and inhibiting its function. One such drug is a small molecule called PF-4866, which is currently being investigated as a potential treatment for various cancers.

Antibodies are another approach that can be used to target TMEM184B. These drugs work by binding to TMEM184B and can be used to treat or diagnose diseases where TMEM184B is over-expressed or mutated. One such antibody is a monoclonal antibody called AMG 701, which is being investigated as a potential treatment for various cancers.

Genetic Modifiers are another approach that can be used to target TMEM184B. These drugs work by modifying the structure or function of TMEM184B, which can lead to the inhibition of its function. One such drug is a small molecule called TK-424, which is being investigated as a potential treatment for various cancers by modulating TMEM184B's expression and function.

Conclusion

In conclusion, TMEM184B is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and subcellular localization make it an attractive target for small molecules, antibodies, and genetic modifiers that can modulate its function and disrupt its role in disease progression. Further research is needed to fully understand the potential of TMEM184B as a drug target and biomarker, and to develop effective treatments for various diseases.

Protein Name: Transmembrane Protein 184B

Functions: May activate the MAP kinase signaling pathway

The "TMEM184B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM184B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets